Genomic alterations of ribosomal protein genes in diffuse large B cell lymphoma
Ribosomal biogenesis (the process of building new ribosomes for protein synthesis), is frequently altered in cancer. Current evidence suggests that ribosomal biogenesis is involved in different processes other than protein synthesis, acting as a dynamic stress sensor regulating cell cycle and apoptosis through modulation of p53 activity (Bursac et al, 2014) .
Genomic screening has recently identified copy number alterations and somatic mutations of ribosomal proteins (RPs) in haematological malignancies such as acute lymphoblastic leukaemia, chronic lymphocytic leukaemia (CLL) and multiple myeloma (MM) (reviewed in Sulima et al, 2017) . In the present study we analysed public datasets containing whole exome sequencing data from multiple studies on mature lymphoid B cell malignancies using the cBioportal website analysis tool (Cerami et al, 2012) , focusing on genomic alterations of ribosomal protein genes (n = 80) and the TP53 gene (which encodes the p53 protein). Copy number variants (CNV) data were available only for DLBCL [The Cancer Genome Atlas (TCGA) provisional dataset; http:// www.cbioportal.org/study?id=dlbc_tcga#summary]. We initially evaluated 7 studies (n = 1016 patients) including DLBCL [3 studies: TCGA provisional dataset + (Lohr et al, 2012 and Braggio et al, 2015) (n = 116 patients)], Mantle cell lymphoma (Be a et al, 2013; 29 patients), MM (Lohr et al, 2014; 205 patients) , CLL (Landau et al, 2013; Puente et al, 2015; 2 studies, 666 patients) .
Genomic alterations of RPs occurred at low frequency in 4% of analysed samples (n = 42) ( Fig 1A) . The only RPs found to be mutated in more than one patient were RPL3 (n = 3), RPL4 (n = 2), RPL10 (n = 3), RPL10A (n = 2), RPL13 (n = 4), RPSA (n = 2), RPS2 (n = 2), RPS9 (n = 2), RPS16 (n = 2), FAU (n = 3) ( Fig 1A) . RP gene mutations were found in DLBCL, CLL and MM and were predominantly missense. Mutations of RPs belonging to the large ribosomal subunit were predominant in DLBCL and MM, whereas CLL was characterized by a higher frequency of mutations of the small ribosomal subunit ( Fig 1B) . Notably, DLBCL showed the highest frequency of RP genomic alterations ( Fig 1C) . More precisely, we identified non-recurrent mutations of 13 different RP genes in 14 (12%) of 116 DLBCL patients ( Fig 1D) . RPL3, RPL13 and FAU were the only RP genes mutated in more than one DLBCL patient sample (2 samples each, 1Á7%). Of note, FAU mutations affected the ubiquitin-like protein FUBI at the N terminus, sparing the RPS30 protein. Affected genes and mutations are summarized in Table I . Residues involved in RPL3 and RPL13 mutations are depicted in Fig 1E. Overall, there was a tendency towards a mutual exclusivity of RP gene mutations, the proportion of patients who had died in the RP mutant versus RP wild-type groups. FAU mutations sparing the RPS30 gene were not considered in this analysis. The analysis was restricted to TP53 wild-type patients. **P value <0Á01, chi-square test. (I) Western blot showing the effect of RPS12 silencing by ShRNAs on P53 stabilization after treatment with doxorubicin in DOHH2 cells. Cells infected with scramble (SCR) and RPS12 ShRNAs (Sh1 and Sh2) were pre-treated with doxycycline 0Á1 lmol/l for 48 h in order to induce RPS12 silencing and then incubated with DMSO or doxorubicin 100 nmol/l for 6 h: P53 levels before and after treatment were then detected by Western blot assay. CLL, chronic lymphocytic leukaemia; DLBCL, diffuse large B cell lymphoma; DMSO, dimethyl sulphoxide; DOXO, doxorubicin; MCL, mantel cell lymphoma; MM, multiple myeloma; RP, ribosomal protein.
as only 2 of 14 patients (14%) showed concomitant mutations of multiple RPs (Fig 1D) .
At the time of this analysis, genome wide CNV data were available only in the TCGA provisional dataset (48 samples) ( Fig 1F) . We found losses of the RPL22 and RPS12 genes in 4 (8%) and 5 (10%) of 48 cases respectively. Due to the novelty, we focused on CNVs of the RPS12 gene ( Fig 1G-I) , which is located on 6q23.2. To validate these findings, we performed genome-wide copy number analysis in an independent cohort of 57 DLBCL patients enrolled in a prospective clinical trial (DLCL04) (Chiappella et al, 2017) , using the OncoScan (TM) assay. The RPS12 gene was deleted in 12 (21%) of 57 samples ( Fig 1G) , being involved in 75% of cases (12/16) with 6q23 deletion. These findings indicate that RPS12 loss is a common genetic event in DLBCL. Considering the TCGA provisional dataset, the cumulative incidence of RP mutations/RPS12 deletions was 29% (14 of 48 cases) ( Fig 1F) .
Given that multiple RPs have been shown to regulate p53 stability in response to nucleolar stress by modulating murine double minute 2 (MDM2)-p53 interactions (Bursac et al, 2014) , we investigated the relationship between RP genomic alterations and the presence of TP53 mutations in DLBCL. Interestingly RP mutations in all DLBCL cohorts were mutually exclusive with TP53 mutations ( Fig 1D) . A similar trend was observed with RPS12 losses (TCGA provisional cohort) ( Fig 1F) . To validate these observations, we performed TP53 DNA Sanger sequencing of the DLCL04 cohort, confirming mutual exclusivity between RPS12 losses and TP53 mutations ( Fig 1G) . Restricting the analysis to patients with available survival data (TCGA cohort), we observed a statistically higher death rate in TP53 wild-type patients harbouring RP mutations compared to those without RP mutations ( Fig 1H) . These data suggest that mutations of RPs could provide lymphoma cells with an alternative mechanism to inactivate the p53mediated response upon nucleolar stress. On the contrary, we did not observe significant differences in outcome between RPS12 deleted and wild-type patients in the DLCL04 cohort (data not shown). In line with this observation, RPS12 silencing did not have a significant impact on p53 stabilization after treatment with doxorubicin in a TP53 wild-type DLBCL cell line ( Fig 1I) .
This report describes, for the first time, genomic alterations of RP genes in a significant fraction of DLBCL cases. Although the functional and clinical consequences of these RP alterations are yet to be determined, these preliminary observations suggest a possible correlation with adverse outcome, which should be investigated in future studies. This notion could be highly significant as many of the currently used chemotherapeutic drugs (such as doxorubicin) are indeed inhibitors of ribosomal biogenesis (reviewed in Bursac et al, 2014) , and drugs selectively targeting ribosomal biogenesis are now in clinical development for haematological malignancies. Finally, the observation that both RP mutations and RPS12 losses were mutually exclusive with TP53 mutations might imply a role for these RP changes in neoplastic transformation. website staff for the kind assistance provided during manuscript preparation.
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The study showed that survival outcomes among patients with stage I NHL are influenced by specific extranodal site of involvement. Compared to nodal disease, cutaneous disease was associated with significantly longer OS in all subtypes except BL and MCL, breast disease was associated with significantly longer OS in FL and SLL, and colonic disease was associated with significantly longer OS in FL, SLL, MZL and MCL. In contrast, gastric and bone disease was associated with inferior OS in FL, BL and PTCL.
Extranodal stage I disease was generally associated with longer OS in FL and MZL but shorter OS in PTCL. Nodal MZL has different biology compared to extranodal MZL and is associated with shorter OS compared to extranodal disease (Swerdlow et al, 2008) . In contrast, extranodal disease, such as in lung, pleura, stomach, small intestine, liver and bone disease, was associated with shorter OS in PTCL. Interestingly, skin (DLBCL, FL, SLL, MZL and PTCL), colon (FL, SLL, MZL and MCL) and breast (FL and SLL) disease were associated with significantly longer OS across several subtypes. In addition to possible biological difference in lymphomas at those sites, these are the sites routinely screened for other cancers (breast and colon) or can be easily found by patients (skin) and thus may have been detected earlier, resulting in a more favourable clinical condition and prognosis.
The prognostic implications of extranodal disease have been evaluated in other studies, mostly in DLBCL (Moller et al, 2004; Lopez-Guillermo et al, 2005; Hui et al, 2010; Castillo et al, 2014) . Castillo et al (2014) analysed the impact of extranodal involvement in patients with DLBCL using
